Boehringer Ingelheim India and Lupin expand collaboration for co-marketing of two oral anti-diabetic drugs

German based pharma major- Boehringer Ingelheim and Lupin announced the expansion of their partnership with plans to market two new oral anti-diabetics recently approved by the Drugs Controller General of India (DCGI) Gibtulio Mee (Empagliflozin+ Metformin) and Ajaduo" (Empagliflozin +Linagliptin). Both these products belong to a novel class of oral anti-diabetic drugs patented in India and will be launched for the first time by an Indian company. The two products will be co-marketed simultaneously by Boehringer Ingelheim and Lupin across India under different brand names.

The Empagliflozin +Linagliptin combination is the world's first approved combination of an SGLT-2 inhibitor and DPP4 inhibitor. In addition to a strong effect on lowering blood sugar levels, it also addresses multiple pathophysiological defects in type 2 diabetes, and is a big step towards improved management of type 2 diabetes. It will also help in reducing the pill burden for patients and help improve adherence to the prescribed treatment.

 

The Empagliflozin + Metformin combination can be given to newly diagnosed patients at higher baseline HbAlc levels and would help manage cardiac complications in patients with type 2 diabetes with heart disease.

Powered by Capital Market - Live News